Detalhe da pesquisa
1.
Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome.
J Transl Med
; 21(1): 756, 2023 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37884937
2.
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.
Int J Mol Sci
; 24(4)2023 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36834611
3.
PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia.
Neurobiol Dis
; 148: 105162, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33171227
4.
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children.
CPT Pharmacometrics Syst Pharmacol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38549500
5.
PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes.
Pharmaceutics
; 15(1)2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36678831
6.
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.
Lancet Neurol
; 22(2): 127-136, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681445
7.
Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES).
Neurol Genet
; 8(6): e200034, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36524101
8.
The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy.
Sci Transl Med
; 13(596)2021 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34078742
9.
Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations.
PLoS One
; 15(5): e0233468, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469975
10.
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Cancer Cell
; 33(3): 495-511.e12, 2018 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29502954
11.
Cell cycle arrest and proapoptotic effects of the anticancer cyclodepsipeptide serratamolide (AT514) are independent of p53 status in breast cancer cells.
Biochem Pharmacol
; 71(1-2): 32-41, 2005 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-16298346
12.
DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin.
Toxicol Sci
; 85(2): 870-9, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15788728
13.
Ionic self-complementarity induces amyloid-like fibril formation in an isolated domain of a plant copper metallochaperone protein.
BMC Struct Biol
; 4: 7, 2004 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-15180901
14.
Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
Pharm Pat Anal
; 2(1): 109-24, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24236974
15.
A tetraguanidinium ligand binds to the surface of the tetramerization domain of protein P53.
Angew Chem Int Ed Engl
; 43(2): 196-8, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14695607
16.
Synthetic ligands able to interact with the p53 tetramerization domain. Towards understanding a protein surface recognition event.
Chembiochem
; 7(7): 1105-13, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16795116
17.
ENPDA: an evolutionary structure-based de novo peptide design algorithm.
J Comput Aided Mol Des
; 19(8): 585-601, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16267689